MiRagen

MiRagen is a biopharmaceutical company that discovers and develops innovative microRNA-targeting therapies to improve human health, specifically in disease areas of high unmet medical need.

The company leverages in-house expertise in miRNA biology, oligonucleotide chemistry, and drug development to evaluate and advance best-in-class technologies and high-potential drug candidates for its own pipeline or in conjunction with strategic partners.

MiRagen recognizes the importance of creating strategic relationships within the biotech and pharmaceutical industries and with academic institutions globally. This collaborative approach is making important contributions in its efforts to create miRNA-targeting therapies.

MiRagen’s areas of focus include hematological malignancies, pathological fibrosis, neuro-degeneration, and cardiovascular disease. In 2011, the company formed a strategic partnership with Servier, a privately-run, French research-based pharmaceutical company, to advance miRNA-targeting drug candidates for the treatment of cardiovascular disease.